This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|July 15, 2013
- Pharmaceutical Technology-07-15-2013
- Volume 2013 eBook
- Issue 1
Impurity Profiling Using Convergence Chromatography and Mass Spectrometry
Author(s)Michael D. Jones, Warren Potts
The authors describe the use of convergence chromatography combined with mass spectrometry for impurity profiling.
Advertisement
Coupling ultra-performance convergence chromatography to mass spectrometry provides an important tool for pharmaceutical analysis.
The authors describe the use of convergence chromatography combined with mass spectrometry for impurity profiling. This was achieved by using metoclopramide and its related substances and metoclopramide drug products as examples.
View
.
Articles in this issue
about 13 years ago
Identification and Quantification of Trace-Level Protein Impuritiesabout 13 years ago
Ultra-High-Speed Analysis of Ibuprofen Using HPLCabout 13 years ago
Characterization with Atomic Force Microscopy, Topographic, and 3D RamanAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement